Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | HNRNPL | CTRPv2 | pan-cancer | AAC | 0.17 | 3e-07 |
mRNA | PNISR | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-07 |
mRNA | LUC7L2 | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-07 |
mRNA | MAD2L2 | CTRPv2 | pan-cancer | AAC | 0.17 | 3e-07 |
mRNA | ARFGEF2 | CTRPv2 | pan-cancer | AAC | -0.17 | 3e-07 |
mRNA | AHNAK | CTRPv2 | pan-cancer | AAC | -0.18 | 3e-07 |
mRNA | BRSK1 | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-07 |
mRNA | EP400 | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-07 |
mRNA | DPYSL5 | CTRPv2 | pan-cancer | AAC | 0.19 | 3e-07 |
mRNA | SULT4A1 | CTRPv2 | pan-cancer | AAC | 0.2 | 3e-07 |